Amyotrophic lateral sclerosis and primary lateral sclerosis: Evidence-based diagnostic evaluation of the upper motor neuron

Neuroimaging Clinics of North America

Volumn 13, Issue 2, 2003, Pages 307-326

  Chan, Stephen ^a   Kaufmann, Petra ^a   Shungu, Dikoma C ^a   Mitsumoto, Hiroshi ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION TENSOR IMAGING; EVIDENCE BASED MEDICINE; HUMAN; MOTONEURON; MOTOR NEURON DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0038729339     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5149(03)00018-2     Document Type: Review

References (112)

1. Mitsumoto H, Chad DA, Pioro EP. Epidemiology. In: Mitsumoto H, Chad DA, Pioro EP, editors, Amyotrophic lateral sclerosis. Contemporary neurology series 49. New York: Oxford Press; 1998. p. 18-33.
2. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci 2001; 191:3-9.
3. Mitsumoto H, Chad DA, Pioro EP. Clinical features. In: Mitsumoto H, Chad DA, Pioro EP, editors. Amyotrophic lateral sclerosis. Contemporary neurology series 49. New York: Oxford Press; 1998. p. 47-64.
4. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
5. Bensimon G, Lacomblez L, Meininger V, et al, for the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-91.
6. Lacomblez L, Bensimon G, Leigh NP, et al, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-31.
7. Stewart A, Sandercock J, Bryan S, et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technol Assess 2001;5:1-97.
8. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-66.
9. Brown Jr RH. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 1995;80:687-92.
10. Brown Jr RH. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments. Ann Neurol 1996;39:145-6.
11. Mitsumoto H, Chad DA, Pioro EP. Excitotoxicity and oxidative stress. In: Mitsumoto H, Chad DA, Pioro EP, editors. Amyotrophic lateral sclerosis. Contemporary neurology series 49. New York: Oxford Press; 1998. p. 197-225.
12. Rothstein JD. Excitotoxicity hypothesis. Neurology 1996;47(Suppl 2):S19-26.
13. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
14. Mitsumoto H. Amyotrophic lateral sclerosis. In: Adelman A, Smith B, editors. Encyclopedia of neuroscience in CD-ROM. New York: Elsevier Health Sciences; 1998.
15. Mitsumoto H, Chad DA, Pioro EP. Treatment trials. In: Mitsumoto H, Chad DA, Pioro EP, editors. Amyotrophic lateral sclerosis. Contemporary neurology series 49. New York: Oxford Press; 1998. p. 329-59.
16. Sharrard WJW. The distribution of the permanent paralysis in the lower limb in poliomyelitis: a clinical and pathological study. J Bone Joint Surg 1955;37:540-8.
17. Swash M, Ingram D. Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry 1988;51:165-8.
18. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci 1999;196:2-12.
19. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993;118:48-55.
20. Pringle CE, Hudson AJ, Munoz DG, et al. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992;115:495-520.
21. Le Forestier N, Maisonobe T, Piquard A, et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 2001;124:1989-99.
22. Rowland LP. Hereditary and acquired spastic paraplegia. In: Rowland LP, editor. Merritt's Neurology. 10th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 703-7.
23. Mackay RP. Course and prognosis in amyotrophic lateral sclerosis. Arch Neurol 1963;8:17-27.
24. Mitsumoto H. Diagnosis and progression of ALS. Neurology 1997;48(Suppl 4):S2-8.
25. Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998;160(Suppl 1):S6-24.
26. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(Suppl):96-107 [The revised criteria are now available at [www.wfnals.org].
27. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House Guidelines: therapeutic trials in amyotrophic lateral sclerosis. J Neurol Sci 1995;129(Suppl):1-10.
28. Iwanaga K, Hayashi S, Oyake M, et al. Neuropathology of sporadic amyotrophic lateral sclerosis of long duration. J Neurol Sci 1997;146:139-43.
29. Brownell B, Oppenheimer D, Trevor-Hughes J. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry 1970;33:338-57.
30. Lawyer T, Netsky MG. Amyotrophic lateral sclerosis: a clinicoanatomic study of fifty-three cases. Arch Neurol Psychiatry 1953;69:171-92.
31. Field AG, Wang E. Evaluation of the patient with nontraumatic headache: an evidence based approach. Emerg Med Clin North Am 1999;17:127-52.
32. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House Diagnostic Criteria. Arch Neurol 2000;57:1171-6.
33. Davenport RJ, Singler RJ, Chancellor AM, et al. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996;60: 147-51.
34. Traynor BJ, Codd MB, Corr B, et al. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 2000;57:109-13.
35. Rowland LP. Hereditary and acquired motor neuron diseases. In: Rowland LP, editor. Merritt's Neurology. 10th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 708-14.
36. Sawaya RA. Foramen magnum meningioma presenting as amyotrophic lateral sclerosis. Neurosurg Rev 1998;21:277-80.
37. Ikusaka M, Iwata M, Sasaki S, Uchiyama S. Progressive dysphagia due to adult Chiari I malformation mimicking amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996;60:357-8.
38. Lo Coco D, Militello A, Piccoli F, et al. Bulbar-onset amyotrophic lateral sclerosis in a patient with Chiari I malformation. Acta Neurol Scand 2001;104:243-5.
39. Wityk RJ. Dural arteriovenous fistula of the spinal cord: an uncommon cause of myelopathy. Semin Neurol 1996;16:27-32.
40. MacGowan DJL, Scelsa SN, Waldron M. An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology 2001;57: 1094-7.
41. Fischer D, Wullner U, Klockgether T, et al. Cervical spondylotic myelopathy and Kennedy syndrome mimicking amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2001;71:412-8.
42. Yagashita A, Nakano I, Oda M, et al. Location of the corticospinal tract in the internal capsule at MR imaging. Radiology 1994;191:455-60.
43. Cheung G, Gawel MJ, Cooper PW, et al. Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. Radiology 1995;194:263-70.
44. Hecht MJ, Fellner F, Fellner C, et al. MRI-FLAIR images of the head show corticospinal tract alterations in ALS patients more frequently than T2-, T1-, and proton-density-weighted images. J Neurol Sci 2001;186:37-44.
45. da Rocha AJ, Maia Junior AC, Nogueira RG, et al. Magnetic resonance findings in amyotrophic lateral sclerosis using a spin echo magnetization transfer sequence: preliminary report. Arq Neuropsiquiatr 1999;57:912-5.
46. Ellis CM, Simmons A, Jones DK, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 1999;53:1051-8.
47. Waragai M. MRI and clinical features in amyotrophic lateral sclerosis. Neuroradiology 1997;39:847-51.
48. Peretti-Viton P, Azulay JP, Trefouret S, et al. MRI of the intracranial corticospinal tracts in amyotrophic and primary lateral sclerosis. Neuroradiology 1999;41: 744-9.
49. Mirowitz S, Sartor K, Gado M, et al. Focal signal intensity variations in the posterior internal capsule: normal MR findings and distinction from pathological findings. Radiology 1989;172:535-9.
50. Rutledge JN, Hilal SK, Silver AJ, et al. Study of movement disorders and brain iron by MR. AJNR Am J Neuroradiol 1987;8:397-411.
51. Abe K, Fujimura H, Kobayashi Y, et al. Degeneration of the pyramidal tracts in patients with amyotrophic lateral sclerosis: a premortem and postmortem magnetic resonance imaging study. J Neuroimaging 1997; 7:208-12.
52. Hofmann E, Ochs G, Pelzl A, et al. The corticospinal tract in amyotrophic lateral sclerosis: an MRI study. Neuroradiology 1998;40:71-5.
53. Chan S, Shungu DC, Douglas-Akinwande A, et al. Motor neuron diseases: comparison of single voxel proton magnetic resonance spectroscopy of the motor cortex with magnetic resonance imaging of the brain. Radiology 1999;212:763-9.
54. Bowen BC, Pattany PM, Bradley WG, et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2000;21:647-58.
55. Thorpe JW, Moseley IF, Hawkes CH, et al. Brain and spinal cord MRI in motor neuron disease. J Neurol Neurosurg Psychiatry 1996;61:314-7.
56. Waragai M, Shinotoh H, Hayashi M, et al. High signal intensity on T1-weighted MRI of the anterolateral column of the spinal cord in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1997;62:88-91.
57. Friedman DP, Tartaglino LM, Fisher A, et al. MR imaging in the diagnosis of intramedullary spinal cord diseases that involve specific neural pathways or vascular territories. AJR Am J Roentgenol 1995;165:515-23.
58. Mawad ME, Hilal SK, Fetell MR, et al. Patterns of spinal cord atrophy by metrizamide CT. AJNR Am J Neuroradiol 1983;4:611-3.
59. Oba H, Araki T, Ohtomo K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993;189:843-6.
60. Ishikawa K, Nagura H, Yokota T, et al. Signal loss in the motor cortex on magnetic resonance images in amyotrophic lateral sclerosis. Ann Neurol 1993;33:218-22.
61. Imon Y, Yamaguchi S, Yamamura Y, et al. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases. J Neurol Sci 1995;134(Suppl):27-32.
62. Hirai T, Korogi Y, Sakamoto Y, et al. T2 shortening in the motor cortex: effect of aging and cerebrovascular diseases. Radiology 1996;199:799-803.
63. Imon Y, Yamaguchi S, Katayama S, et al. A decrease in cerebral cortex intensity on T2-weighted with ageing images of normal subjects. Neuroradiology 1998;40:76-80.
64. Iwasaki Y, Ikeda K, Shiojima T, et al. Clinical significance of hypointensity in the motor cortex on T2-weighted images. Neurology 1994;44:1181.
65. Kiernan JA, Hudson AJ. Frontal lobe atrophy in motor neuron diseases. Brain 1994;117:747-57.
66. Ellis CM, Suckling J, Amaro E, et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001;57:1571-8.
67. Van Zandijcke M, Casselman J. Involvement of corpus callosum in amyotrophic lateral sclerosis shown by MRI. Neuroradiology 1995;37:287-8.
68. Yamauchi H, Fukuyama H, Ouchi Y, et al. Corpus callosum atrophy in amyotrophic lateral sclerosis. J Neurol Sci 1995;134:189-96.
69. Kato Y, Matsumura K, Kinosada Y, et al. Detection of pyramidal tract lesions in amyotrophic lateral sclerosis with magnetization-transfer measurements. AJNR Am J Neuroradiol 1997;18:1541-7.
70. Tanabe JL, Vermathen M, Miller R, et al. Reduced MTR in the corticospinal tract and normal T2 in amyotrophic lateral sclerosis. Magn Reson Imag 1998;16:1163-9.
71. Pioro EP. MR spectroscopy in amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci 1997;152(Suppl 1):S49-53.
72. Kalra S, Arnold DL, Cashman NR. Biological markers in the diagnosis and treatment of ALS. J Neurol Sci 1999;165(Suppl):S27-32.
73. 1H-MRS) in ALS. ALS 2000;1(Suppl 2):S7-16.
74. Bowen BC, Bradley WG. Amyotrophic lateral sclerosis: the search for a spectroscopic marker of upper motoneuron involvement. Arch Neurol 2001;58:714-6.
75. Hanstock CC, Cwik VA, Wayne Martin WR. Reduction in metabolite transverse relaxation times in amyotrophic lateral sclerosis. J Neurol Sci 2002; 198:737-41.
76. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999;53:71-9.
77. Cwik VA, Hanstock CC, Allen PS, et al. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 1998;50:72-7.
78. Rooney WE, Miller RG, Gelinas D, et al. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 1998;50:1800-5.
79. 1H MRSI in amyotrophic lateral sclerosis. Magn Reson Med 2001;45:513-6.
80. Block W, Karitzky J, Traber F, et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol 1998;55:931-6.
81. Jones AP, Gunawardena WJ, Coutinho CMA, et al. Preliminary results of proton magnetic resonance spectroscopy in motor neuron disease (amyotrophic lateral sclerosis). J Neurol Sci 1995;129(Suppl):85-9.
82. Abe K, Takanishi M, Watanabe Y, et al. Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 2001;43:537-41.
83. Giroud M, Walker P, Bernard D, et al. Reduced brain N-acetylaspartate in frontal lobes suggests neuronal loss in patients with amyotrophic lateral sclerosis. Neurol Res 1996;18:241-3.
84. Ellis CM, Simmons A, Andrews C, et al. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology 1998;51:1104-9.
85. 1H spectroscopy in patients with amyotrophic lateral sclerosis. J Neuroimaging 2001;11:293-7.
86. Pioro EP, Antel JP, Cashman NR, et al. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994;44:1933-8.
87. 1H MRSI. Neurology 2002;58:773-9.
88. Gredal O, Rosenbaum S, Topp S, et al. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997;48:878-81.
89. Pohl C, Block W, Karitzky J, et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 2001;58:729-35.
90. 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001;43:189-97.
91. Kalra S, Cashman N, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757-61.
92. 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. J Neurol Sci 1999;169:84-6.
93. Dechent P, Pouwels PJW, Wilken B, et al. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol 1999;277:R698-704.
94. Vielhaber S, Kaufmann J, Kanowski M, et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 2001;172: 377-82.
95. Udaka E, Sawada H, Seriu N, et al. MRI and SPECT findings in amyotrophic lateral sclerosis: demonstration of upper motor neurone involvement by clinical neuroimaging. Neuroradiology 1992;34:389-93.
96. Abe K, Fujimara H, Toyoka M, et al. Single-photon emission computed tomographic investigation of patients with motor neuron disease. Neurology 1993;43:1569-73.
97. 123I-amphetamine single photon emission computed tomography in motor neuron disease. Eur Neurol 1989;29:255-60.
98. 99mTc]-d,1-HMPAO SPECT study. J Neurol Sci 1992;107:19-28.
99. Caselli RJ, Smith BE, Osborne D. Primary lateral sclerosis: a neuropsychological study. Neurology 1995;45: 2005-9.
100. Dalakas MC, Hatazawa J, Brooks R, et al. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987;22:580-6.
101. Hatazawa J, Brooks RA, Dalakas MC, et al. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J Comp Assist Tomogr 1988; 12:630-6.
102. Ludolph AC, Langen KJ, Regard M, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomographic study. Acta Neurol Scand 1992;85:81-9.
103. 11C] flumazenil. Brain 2000;123:2289-96.
104. Kew JJM, Leigh PN, Playford ED, et al. Cortical function in amyotrophic lateral sclerosis: a positron emission tomography study. Brain 1993;116:655-80.
105. Kew JJM, Leigh PN, Playford ED, et al. Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis. Neurology 1994;44:1101-10.
106. Abrahams S, Goldstein LH, Kew JJM. Frontal lobe dysfunction in amyotrophic lateral sclerosis: a PET study. Brain 1996;119:2105-20.
107. Brooks BR, Bushara K, Khan A, et al. Functional magnetic resonance (fMRI) clinical studies in ALS paradigms, problems and promises. ALS 2000; 1(Suppl 2):S23-32.
108. Konrad C, Henningsen H, Bremer J, et al. Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance study. Exp Brain Res 2002;143:51-6.
109. Poloni M, Mascherpa C, Faggi L, et al. Cerebral atrophy in motor neuron disease evaluated by computed tomography. J Neurol Neurosurg Psychiatry 1982;45:1102-5.
110. Kato S, Hayashi H, Yagishita A. Involvement of the frontotemporal lobe and limbic system in amyotrophic lateral sclerosis: as assessed by serial computed tomography and magnetic resonance imaging. J Neurol Sci 1993;116:52-8.
111. Triggs WJ, Menkes D, Onorato J, et al. Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease. Neurology 1999;53:605-11.
112. Karitzky J, Ludolph AC. Imaging and neurochemical markers for diagnosis and disease progression in ALS. J Neurol Sci 2001;191:35-41.